Zacks Research Expects Stronger Earnings for Gilead Sciences

Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) - Research analysts at Zacks Research boosted their Q2 2025 EPS estimates for shares of Gilead Sciences in a research note issued on Thursday, May 8th. Zacks Research analyst E. Bagri now anticipates that the biopharmaceutical company will post earnings per share of $1.93 for the quarter, up from their prior estimate of $1.92. The consensus estimate for Gilead Sciences' current full-year earnings is $7.95 per share. Zacks Research also issued estimates for Gilead Sciences' Q3 2025 earnings at $2.07 EPS, Q4 2025 earnings at $1.99 EPS, FY2025 earnings at $7.80 EPS, Q1 2026 earnings at $1.68 EPS, Q3 2026 earnings at $2.21 EPS and Q4 2026 earnings at $2.31 EPS.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.04. The firm had revenue of $6.67 billion for the quarter, compared to the consensus estimate of $6.77 billion. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Gilead Sciences's quarterly revenue was down .3% compared to the same quarter last year. During the same period last year, the firm posted ($1.32) EPS.

GILD has been the topic of several other research reports. Royal Bank of Canada raised their target price on shares of Gilead Sciences from $84.00 to $90.00 and gave the company a "sector perform" rating in a research note on Wednesday, February 12th. JPMorgan Chase & Co. lifted their price objective on shares of Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research note on Thursday, March 27th. Wells Fargo & Company lifted their price objective on shares of Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 5th. Deutsche Bank Aktiengesellschaft raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and lifted their price objective for the stock from $80.00 to $120.00 in a research note on Tuesday, February 18th. Finally, Piper Sandler lifted their target price on shares of Gilead Sciences from $105.00 to $110.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 12th. Nine analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Gilead Sciences has an average rating of "Moderate Buy" and an average price target of $110.55.

Gilead Sciences Price Performance

Gilead Sciences stock traded down $2.39 during trading hours on Monday, hitting $101.43. 8,314,965 shares of the company traded hands, compared to its average volume of 7,623,416. The firm has a market cap of $126.30 billion, a P/E ratio of 274.14, a P/E/G ratio of 0.71 and a beta of 0.26. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The firm's 50-day simple moving average is $107.00 and its two-hundred day simple moving average is $99.49. Gilead Sciences has a 1-year low of $62.07 and a 1-year high of $119.96.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in GILD. Smallwood Wealth Investment Management LLC bought a new stake in shares of Gilead Sciences in the 1st quarter valued at about $25,000. HHM Wealth Advisors LLC increased its stake in shares of Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 154 shares during the last quarter. YANKCOM Partnership bought a new stake in shares of Gilead Sciences in the 4th quarter valued at about $28,000. Decker Retirement Planning Inc. bought a new stake in shares of Gilead Sciences in the 4th quarter valued at about $29,000. Finally, Goodman Advisory Group LLC bought a new stake in Gilead Sciences during the 1st quarter worth approximately $29,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 137,676 shares of the company's stock in a transaction dated Wednesday, February 12th. The shares were sold at an average price of $102.22, for a total transaction of $14,073,240.72. Following the transaction, the chief financial officer now owns 171,223 shares in the company, valued at $17,502,415.06. This represents a 44.57% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In the last quarter, insiders have sold 160,605 shares of company stock worth $16,718,136. Corporate insiders own 0.27% of the company's stock.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be paid a $0.79 dividend. The ex-dividend date of this dividend is Friday, June 13th. This represents a $3.16 annualized dividend and a dividend yield of 3.12%. Gilead Sciences's dividend payout ratio is presently 66.53%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.